Biogen to Acquire Apellis Pharmaceuticals in $4B+ Deal

SEC 8-K Filing Notice

Company: Biogen Inc. (BIIB) Filing Date: 2026-03-31 Accession Number: 0001193125-26-134889

Items Filed

Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Summary

Biogen Inc. announced it has entered into a definitive agreement to acquire Apellis Pharmaceuticals, Inc. for $41.00 per share in cash, plus one contingent value right (CVR) potentially worth up to $4.00 per share, totaling over $4 Billion. The acquisition will be executed through a tender offer followed by a merger, with Apellis becoming a wholly-owned subsidiary of Biogen. The Apellis board has unanimously approved the deal and recommends that stockholders accept the offer.

Key Takeaways

Biogen to acquire Apellis Pharmaceuticals for $41/share + CVR (up to $4/share).
Acquisition will proceed via tender offer followed by a merger.
Apellis board unanimously recommends stockholders accept the offer.
The deal is subject to customary closing conditions, including regulatory approvals and a minimum tender of shares.
Apellis may terminate the agreement under certain circumstances, subject to a $205 million termination fee.

Analysis

This acquisition signals Biogen's strategic focus on expanding its portfolio, likely targeting Apellis's complement-targeted therapies. For investors, this move could be seen positively if the acquisition strengthens Biogen's long-term growth prospects and diversifies its revenue streams. Competitors in the complement therapeutics space will likely reassess their strategies in light of Biogen's increased presence. The broader pharmaceutical market may see increased M&A activity as companies seek to bolster their pipelines and market positions.

This post was automatically generated from an SEC 8-K filing.